Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Intellia Thera CS (NQ: NTLA)
16.63 USD  +0.14 (+0.85%)
Official Closing Price  /  Updated: 4:56 PM EST, Dec 12, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 420,900
Open 16.84
Bid (Size) 13.00 (1)
Ask (Size) 18.88 (2)
Prev. Close 16.49
Today's Range 16.52 - 17.14
52wk Range 15.55 - 35.99
Shares Outstanding 43,089,810
Dividend Yield N/A
Performance
YTD
-22.69%
-22.69%
1 Month
-3.87%
-3.87%
3 Month
-45.06%
-45.06%
6 Month
-35.17%
-35.17%
1 Year
-9.10%
-9.10%
Top News
More News
Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced an expansion of... Read More
from GlobeNewswire News Releases
Intellia Therapeutics to Present at November Healthcare Investor Conferences
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will participate in the... Read More
from GlobeNewswire News Releases
More News
Read More
Consolidated Research: 2018 Summary Expectations for STORE Capital, Ares Commercial Real Estate, Intellia Therapeutics, City Office REIT, RealPage, and Data I/O — Fundamental Analysis, Key Performance
from GlobeNewswire News Releases
Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments
from GlobeNewswire News Releases
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2018 Earnings and Corporate Developments
from GlobeNewswire News Releases
Intellia Therapeutics Names Glenn Goddard as New Chief Financial Officer
from GlobeNewswire News Releases
Intellia Therapeutics Presents New Data in In Vivo and Ex Vivo Programs at the 26th Annual Congress of the European Society of Gene and Cell Therapy
from GlobeNewswire News Releases
Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'
category Analyst Color , DRNA , Mani Foroohar , and 19 more.
from Benzinga
This Biotech Stock Could Launch Its First CRISPR Drug In 2022
from Investor's Business Daily
The Math Shows XBI Can Go To $132
category ETFs
from ETF Channel
Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018
category Market News , CRSP , VRTX , and 2 more.
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X